Drugs / DA-3031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00959777 | — | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-3031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00959777 ↗ |
| Known as | pegylated filgrastim | “DA-3031 is a newly developed pegylated filgrastim, a recombinant human granulocyte colony-stimulating factor, that is expected to have an extended duration of action compared...” PMID 24078278 ↗ Nov 2013 |
| Modality | Protein / enzyme biologic | “DA-3031 is a newly developed pegylated filgrastim, a recombinant human granulocyte colony-stimulating factor, that is expected to have an extended duration of action compared...” PMID 24078278 ↗ Nov 2013 |
| Route | Subcutaneous | “Forty subjects received subcutaneous single doses of 1.8, 3.6, 6, or 18 mg of DA-3031 or placebo in a dose block-randomized, double-blind, dose-escalation design.” PMID 24078278 ↗ Nov 2013 |